ArticleCureus2025
Apocrine Breast Carcinoma With an Atypical Immunohistochemical Profile: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common malignancy among women worldwide and encompasses a wide variety of histopathological subtypes. While invasive ductal carcinoma (IDC) represents the most prevalent form, rare variants such as apocrine carcinoma (AC) also warrant particular attention. Classically, AC of the breast is defined by apocrine morphology, negativity for hormonal receptors (estrogen receptor (ER), progesterone receptor (PR)), and strong positivity for the androgen receptor (AR). However, the present case involving a 37-year-old woman who detected a nodule at the junction of the lower quadrants of the right breast illustrates an atypical variant of this tumor subtype. Histological examination revealed two lesions displaying typical apocrine carcinomatous proliferation but with an unusual immunohistochemical profile: ER expression at 80%, PR expression at 5%, and human epidermal growth factor receptor 2 (HER2) overexpression. This deviation from the classical apocrine profile highlights the biological heterogeneity of these tumors and underscores the importance of thorough characterization to optimize therapeutic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.